118 related articles for article (PubMed ID: 27592744)
1. Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.
Li SW; Liu Y; Sampson PB; Patel NK; Forrest BT; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Hodgson R; Beletskaya I; Mao G; Mason JM; Wei X; Luo X; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
Bioorg Med Chem Lett; 2016 Oct; 26(19):4625-4630. PubMed ID: 27592744
[TBL] [Abstract][Full Text] [Related]
2. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
[TBL] [Abstract][Full Text] [Related]
3. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
[TBL] [Abstract][Full Text] [Related]
4. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
[TBL] [Abstract][Full Text] [Related]
5. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
Liu Y; Lang Y; Patel NK; Ng G; Laufer R; Li SW; Edwards L; Forrest B; Sampson PB; Feher M; Ban F; Awrey DE; Beletskaya I; Mao G; Hodgson R; Plotnikova O; Qiu W; Chirgadze NY; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
J Med Chem; 2015 Apr; 58(8):3366-92. PubMed ID: 25763473
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel indolin-2-ones as potent anticancer compounds.
Zhou A; Yan L; Lai F; Chen X; Goto M; Lee KH; Xiao Z
Bioorg Med Chem Lett; 2017 Aug; 27(15):3326-3331. PubMed ID: 28625363
[TBL] [Abstract][Full Text] [Related]
7. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
Ma F; Liu P; Lei M; Liu J; Wang H; Zhao S; Hu L
Eur J Med Chem; 2017 Feb; 127():72-86. PubMed ID: 28038328
[TBL] [Abstract][Full Text] [Related]
9. Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor.
Sun Y; Wang L; Sun Y; Wang J; Xue Y; Wu T; Yin W; Qin Q; Sun Y; Wang H; Gao Y; Yang H; Zhao D; Cheng M
Eur J Med Chem; 2022 Dec; 243():114714. PubMed ID: 36063666
[TBL] [Abstract][Full Text] [Related]
10. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
11. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.
Lohse I; Mason J; Cao PM; Pintilie M; Bray M; Hedley DW
Oncotarget; 2017 Jan; 8(2):3064-3071. PubMed ID: 27902970
[TBL] [Abstract][Full Text] [Related]
12. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
Velaparthi U; Wittman M; Liu P; Carboni JM; Lee FY; Attar R; Balimane P; Clarke W; Sinz MW; Hurlburt W; Patel K; Discenza L; Kim S; Gottardis M; Greer A; Li A; Saulnier M; Yang Z; Zimmermann K; Trainor G; Vyas D
J Med Chem; 2008 Oct; 51(19):5897-900. PubMed ID: 18763755
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
[TBL] [Abstract][Full Text] [Related]
14. New (E)-1-alkyl-1H-benzo[d]imidazol-2-yl)methylene)indolin-2-ones: Synthesis, in vitro cytotoxicity evaluation and apoptosis inducing studies.
Sharma P; Thummuri D; Reddy TS; Senwar KR; Naidu VGM; Srinivasulu G; Bharghava SK; Shankaraiah N
Eur J Med Chem; 2016 Oct; 122():584-600. PubMed ID: 27448916
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of spiro[cyclopropane-1,3'-indolin]-2'-ones as potential anticancer agents.
Reddy CN; Nayak VL; Mani GS; Kapure JS; Adiyala PR; Maurya RA; Kamal A
Bioorg Med Chem Lett; 2015 Oct; 25(20):4580-6. PubMed ID: 26330077
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
18. [Synthesis of 1-furfuryl-indolin-2-one derivatives and preliminary evaluation of their antitumor activities].
Dong XC; Zhou FS; Zheng JB; Wen R
Yao Xue Xue Bao; 2008 Jan; 43(1):54-9. PubMed ID: 18357732
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of a potent PLK4 inhibitor WY29 with 1H-pyrazolo[3,4-d]pyrimidine scaffold.
Wang L; Sun Y; Wang J; Xue Y; Sun Y; Qin Q; Sun Y; Zhao D; Cheng M
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200490. PubMed ID: 36442843
[TBL] [Abstract][Full Text] [Related]
20. Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.
Chen T; Sorna V; Choi S; Call L; Bearss J; Carpenter K; Warner SL; Sharma S; Bearss DJ; Vankayalapati H
Bioorg Med Chem Lett; 2017 Dec; 27(24):5473-5480. PubMed ID: 29150397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
